vTv Therapeutics Inc. filings document the regulatory record of a Nasdaq-listed, late-stage biopharmaceutical company developing oral small-molecule candidates for diabetes and other chronic diseases. Form 8-K reports cover financial results, Regulation FD investor presentations, material agreements, and clinical or regulatory disclosures tied to cadisegliatin and other pipeline assets.
The company’s filings also disclose licensing arrangements involving vTv Therapeutics LLC and HPP737, capital-structure and security-related matters, and governance information in proxy materials. Definitive proxy statements describe board matters, executive compensation, equity awards, shareholder voting items, and related corporate-governance disclosures.
vTv Therapeutics Inc. executive vice president and CFO Michael Stephen Tung received a grant of employee stock options reported as a Form 4 transaction. The award covers 44,969 options with an exercise price of $36.92 per share, increasing his directly held option position to 89,969 options following the grant. According to the footnote, the options vest 25% on the first anniversary of the grant date and then in equal quarterly installments afterward, spreading the ability to exercise over time.
vTv Therapeutics Inc. reported an insider equity award for its President, CEO and Executive Chairperson, Paul J. Sekhri. On February 17, 2026, he was granted stock options tied to 140,000 shares of Class A common stock at an exercise price of $36.92 per share. The options vest 25% on the first anniversary of the grant date and then in equal quarterly installments. Following this grant, Sekhri’s directly held Class A interest reported in this filing totals 392,212 shares.
vTv Therapeutics Inc. reported that its subsidiary vTv Therapeutics LLC entered into a Second Amendment to its license agreement with Newsoara Biopharma Co., Ltd. on January 30, 2026. The amendment expands Newsoara’s rights to vTv’s PDE4 inhibitor HPP737 to cover all countries.
In return, Newsoara will pay an upfront fee of $20 million, development milestone payments of up to $50 million, and sales-related milestones of up to $65 million. The agreement also includes royalties in the mid single digits based on sales volumes, creating multiple potential revenue streams tied to HPP737’s progress and commercial performance.
vTv Therapeutics Inc. reported Q3 2025 results. The company recorded no revenue, with operating expenses of $10.7 million (research and development $7.0 million; general and administrative $3.7 million), leading to a net loss attributable to vTv of $8.7 million and basic/diluted loss per share of $1.08.
Liquidity improved, with cash and cash equivalents $98.5 million at September 30, 2025, supported by an August private placement that brought aggregate gross proceeds of approximately $80.0 million (net financing cash inflow $77.8 million). Management now indicates there is no longer substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance.
Development advanced: the FDA removed the cadisegliatin clinical hold on March 14, 2025, and the CATT1 Phase 3 protocol was shortened to six months; top‑line data are expected in the second half of 2026. Shares outstanding were 3,938,018 Class A and 241 Class B as of November 6, 2025.
vTv Therapeutics Inc. furnished an 8‑K announcing financial results for the fiscal quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing its results.
The report states the information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, which limits applicability of certain liabilities and incorporation by reference unless specifically cited.
vTv Therapeutics Inc. filed an S-3 shelf registering up to 15,876,640 shares of Class A common stock and related warrants and pre-funded warrants. The filing reports positive clinical data for cadisegliatin from the SimpliciT-1 trial showing a 40% reduction in severe and symptomatic hypoglycemia and a statistically significant improvement in HbA1c versus placebo, with fewer abnormal serum or urine ketone findings. A Phase 1 mechanistic study found no increased ketoacidosis risk during acute insulin withdrawal. The company reported that an ADME radiochromatographic signal was identified as an experimental artifact and that the FDA lifted a clinical hold on March 14, 2025, allowing clinical development to resume in Q2 2025. The registration discloses Pre-Funded Warrants exercisable at $0.01 and Common Warrants with a weighted average exercise price of $22.98. The filing incorporates audited 2024 financials with Ernst & Young LLP noting an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Reporting persons led by Dr. Srinivas Akkaraju disclosed a material holding in vTv Therapeutics Inc. The amendment describes final closing of an August 2025 private placement on September 22, 2025, in which Samsara Opportunity Fund paid $15.0 million to acquire 106,000 Class A shares plus Pre-Funded Warrants exercisable for up to 877,214 shares and Common Warrants exercisable for up to 983,214 shares. Aggregate beneficial ownership reported for the group equals 343,223 shares, representing 9.9% of Class A stock on the basis stated. Certain warrant exercises are blocked to prevent beneficial ownership exceeding 9.99%.
Srinivas Akkaraju, a director of vTv Therapeutics (VTVT), reported on Form 4 that related investment vehicles managed or controlled by him participated in a securities purchase closed on September 22, 2025. Samsara Opportunity Fund, L.P. purchased 106,000 shares of Class A common stock at $15.265 per share and received pre-funded warrants exercisable for up to 877,214 shares plus common warrants exercisable for up to 983,214 shares. Separately, securities held by Samsara BioCapital, L.P. include 206,784 shares of Class A common stock, pre-funded warrants exercisable for up to 1,548,101 shares, and common warrants exercisable for up to 655,523 shares. The pre-funded warrants are exercisable at $0.01 with no expiration; common warrants have an exercise price of $22.71 and expire by September 3, 2030 or upon certain conditions. Ownership is reported as indirect through the named investment entities and the reporting person disclaims direct beneficial ownership except to the extent of his pecuniary interest.
vTv Therapeutics Inc. filed a current report describing its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. On September 10, 2025, the company will join a fireside chat scheduled from 2:35 to 3:10 p.m. EST, available as a live audio webcast and on demand.
The company notes that a link to the webcast will be posted on its website. This communication is furnished under Regulation FD and is expressly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings.